Clinical Trial Update: Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Carmustine wafer in combination with Retifanlimab and radiation, with or without temozolomide, in glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• GLIADEL wafer (carmustine)
• Retifanlimab (retifanlimab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Glioblastoma Multiforme | Phase 1 | Status: RECRUITING